Videos

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.

Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

There is an evolution of thinking about how this is treated and investigational therapies are looking to help these patients improve not only their medical conditions but give them back their quality-of-life.

Evidence demonstrates how these therapies are prescribed around patients’ races.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.

Investigators surmise a natural bat exposure within certain areas of the world may correspond with lower COVID-19 incidence rates.

WHO and CDC have laid out some ambitious goals for the treatment of hepatitis C, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, offers some insights and commentary on whether he feels it is realistic to consider the eradication of this stubborn and subtle virus.

Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

A biotech company is utilizing this platform to rid people of the virus using a technology that differs from CRISPR-Cas9.

Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.

A new study finds there are more pharmacies than physician practices in these areas; however, these inequities offer an opportunity for pharmacists to step-in and provide vaccine education and administration.

The benefits outweigh the possible rebound of symptoms, according to an investigator who studied the antiviral.

Working to Fight AMR is working in Washington DC to help pass policies in Congress to help alleviate this significant issue.

Dr. Arlene Sena and her team are working to develop a syphilis vaccine, “But we need to know what’s circulating worldwide first.”

Aethlon Medical’s proprietary Hemopurifier is being studied to treat COVID-19, and they recently reported results.

The start of Men’s Health Week offers an opportunity for men to get screened for a variety of health issues and be proactive with their health including those who might be at risk of HIV and may benefit from PrEP.

Tecovirimat (Tpoxx) is an antiviral agent that is already indicated for another orthopoxvirus, smallpox. And studies are ongoing to see if it has potential efficacy in treating monkeypox.

Although underutilized, this highly efficacious vaccine can help prevent numerous cancers including the most prevalent—head and neck and cervical cancers.